Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 10/10/18 → 10/1/24 |
Funding
- Celgene International II Sarl: $68,007.00
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
- Flomenhoft, Deborah (PI)